INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $11,844,013 | -2.4% | 218,726 | -5.6% | 0.83% | +6.6% |
Q4 2021 | $12,131,732 | +41.0% | 231,787 | +0.5% | 0.78% | +29.8% |
Q3 2021 | $8,602,136 | +79.4% | 230,744 | +96.4% | 0.60% | +86.6% |
Q2 2021 | $4,794,799 | -53.0% | 117,462 | -60.9% | 0.32% | -58.3% |
Q1 2021 | $10,198,917 | -10.0% | 300,587 | -15.6% | 0.77% | -42.3% |
Q4 2020 | $11,328,273 | +149.8% | 356,235 | +101.5% | 1.33% | +31.8% |
Q3 2020 | $4,535,610 | – | 176,758 | – | 1.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |